Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as a promising non-invasive biomarker in clinical oncology. Analysis of ctDNA opens up new avenues for individualized cance...
Guardado en:
Autores principales: | Yan Peng, Wuxuan Mei, Kaidong Ma, Changchun Zeng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6e3c221d463c466ba5b4c9263ea35e00 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Lionel Larribère, et al.
Publicado: (2021) -
Detection Technology and Prospects of Clinical Application of Circulating Tumor Cells in Pancreatic Cancer
por: YANG Xiaoying, et al.
Publicado: (2021) -
Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer
por: Fang Yang, et al.
Publicado: (2021) -
Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
por: Natasha Honoré, et al.
Publicado: (2021) -
Liquid Biopsy and Primary Brain Tumors
por: Robert H. Eibl, et al.
Publicado: (2021)